2007-03-12

Isotechnika Receives USAN Approval for Generic Name for Lead Immunosuppressive Drug


Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announcedtoday that the Company has received approval from United StatesAdopted Name (USAN) for naming of its lead immunosuppressive drug,ISA247.

The name, voclosporin, is now being reviewed by the InternationalNonproprietary Name (INN) expert committee. The INN is scheduled topublish the proposed list of approved names sometime in mid 2007.Official notification from the INN would allow Isotechnika to use thename voclosporin in labelling, publications, and on drug information.The name will serve to identify the active pharmaceutical substanceduring the drugs' life-time worldwide.

ISA247 (voclosporin) is a calcineurin inhibitor, currently beinginvestigated in a Phase 3 European/Canadian trial for the treatmentof moderate to severe psoriasis and a Phase 2b North American trialfor the prevention of organ rejection in kidney transplant patientsand as a treatment for uveitis in three separate pivotal Phase2/Phase 3 trials. The latter trial is being coordinated by ourpartner, Lux Biosciences.

"Moving toward the name of voclosporin from the previousnomenclature of ISA247 should assist us in initiating our commercialbranding process. The next step in the naming process is to requestthat the USAN approved name, voclosporin, be approved by theInternational Nonproprietary Name (INN) Programme of the World HealthOrganization (WHO). Pending receipt of this INN approval, ISA247will, in all future materials, be referred to by its new genericname, voclosporin," commented Dr. Randall Yatscoff, Isotechnika'sPresident & CEO.

About Isotechnika

Isotechnika Inc. is an international biopharmaceutical companyheadquartered in Edmonton, Alberta, Canada. Drawing upon itsexpertise in medicinal chemistry and immunology, the Company isfocused on the discovery and development of novel immunosuppressivetherapeutics that are safer than currently available treatments. Itsentrepreneurial management and world-class team of scientists arebuilding a pipeline of immunosuppressive drug candidates fortreatment of autoimmune diseases and for use in the prevention oforgan rejection in transplantation. Isotechnika looks to become theleader in development of immunosuppressant therapies.

Isotechnika's lead compound, ISA247 has successfully completed aPhase 3 Canadian trial for the treatment of moderate to severepsoriasis. ISA247 is currently being investigated in a combined Phase3 European/Canadian psoriasis trial and a Phase 2b North Americantrial for the prevention of kidney graft rejection. The Company alsohas an additional immunosuppressive compound in its drug pipeline,TAFA93 which successfully completed Phase 1 clinical trials.

Isotechnika Inc. is a publicly traded company on the Toronto StockExchange under the symbol "ISA". More information on Isotechnika canbe found at www.isotechnika.com.

Partnerships with Isotechnika Inc.

Isotechnika Inc. signed a collaboration agreement with Hoffman LaRoche on April 9, 2002, which licensed the worldwide rights todevelop and commercialize voclosporine for all transplantindications.

On September 30, 2005, Isotechnika Inc. entered into an exclusiveworldwide licensing agreement with Atrium Medical Corporation for theuse of voclosporine and TAFA93 specifically with drug eluting devicesfor the non-systemic treatment of vascular, cardiovascular, targetvessel and tissue disorders.

Isotechnika Inc. and Cellgate Inc. signed an option agreement onApril 25, 2006, granting Isotechnika the option to obtain anexclusive license to develop and commercialize conjugates consistingof Cellgate's patented transporter technology for the topicaldelivery of voclosporine in patients suffering from mild to moderatepsoriasis.

On May 25, 2006, Isotechnika Inc. signed an agreement with LuxBiosciences, Inc. of Jersey City, New Jersey granting Lux Biosciencesworldwide rights to develop and commercialize Isotechnika's leaddrug, voclosporine for the treatment and prophylaxis of allophthalmic diseases.

Forward-Looking Statements

This press release may contain forward-looking statements. Forwardlooking statements, including the Company's belief as to thepotential of its products, the Company's expectations regarding theissuance of additional patents and the Company's ability to protectits intellectual property, involve known and unknown risks anduncertainties, which could cause the Company's actual results todiffer materially from those in the forward looking statements. Suchrisks and uncertainties include, among others, the availability offunds and resources to pursue research and development projects, theability to economically manufacture its products, the potential ofits products, the success and timely completion of clinical studiesand trials, the Company's ability to successfully commercialize itsproducts, the ability of the Company to defend its patents frominfringement by third parties, and the risk that the Company'spatents may be subsequently shown to be invalid or infringe thepatents of others. Investors should consult the Company's quarterlyand annual filings with the Canadian commissions for additionalinformation on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing unduereliance on forward-looking statements.

.

ots Originaltext: Isotechnika Inc.Im Internet recherchierbar: http://www.presseportal.de

Contact:For further information: Dr. Randall Yatscoff, President & CEO, Isotechnika Inc.,+1(780)-487-1600-(246), +1(780)-484-4105 (fax), ryatscoff@isotechnika.com; Stephanie Gillis-Paulgaard, Director, Corporate Communications, Isotechnika Inc., +1(780)-487-1600-(243), +1(780)-487-4105 (fax), sgillis-paulgaard@isotechnika.com (ISA.)

Isotechnika Inc.

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs

News

Isotechnika Receives USAN Approval for Generic Name for Lead Immunosuppressive Drug

Medizin-News